High materiality8/10
Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs
Why it may matterVerify against the original reporting
Buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Goldman Sachs adds VRTX to US Conviction List; target $653; price $544.52.
- Goldman Sachs adds VRTX to US Conviction List; target $653; price $544.52.
Key facts
- 01
Target: $653
- 02
Posted price: $544.52
- 03
Analyst firm: Goldman Sachs
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.